Literature DB >> 17122451

Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights.

W Stevens1, H Koene, J J Zwaginga, G Vreugdenhil.   

Abstract

Idiopathic thrombocytopenic purpura (ITP) is an immune-mediated thrombocytopenia. The diagnosis is made after exclusion of other secondary causes of thrombocytopenic disorders. The primary treatment goal is to prevent severe bleeding rather than achieve normal platelet counts. In adults ITP usually has an insidious onset and chronic course. Although ITP is a relatively common haematological disorder, there are important unresolved issues in its management, especially for chronic refractory ITP patients. New therapeutic agents have changed strategies for ITP treatment. This article reviews the treatment indications and options of chronic ITP in adults in the literature and compares them with the treatment indications and treatment options used by the Dutch internist.

Entities:  

Mesh:

Year:  2006        PMID: 17122451

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  10 in total

Review 1.  Childhood immune thrombocytopenia: Clinical presentation and management.

Authors:  Mohamed El Faki Osman
Journal:  Sudan J Paediatr       Date:  2012

2.  Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist.

Authors:  Mohamed E Osman
Journal:  Sudan J Paediatr       Date:  2012

3.  Refractory chronic immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia.

Authors:  Satoshi Horino; Takeshi Rikiishi; Hidetaka Niizuma; Hiroshi Abe; Yuko Watanabe; Masaei Onuma; Yoshiyuki Hoshi; Yoji Sasahara; Miyako Yoshinari; Takuro Kazama; Yutaka Hayashi; Satoru Kumaki; Shigeru Tsuchiya
Journal:  Int J Hematol       Date:  2009-10-10       Impact factor: 2.490

4.  A review of immune thrombocytopenic purpura: focus on the novel thrombopoietin agonists.

Authors:  Meaghan Khan; Joseph Mikhael
Journal:  J Blood Med       Date:  2010-03-23

5.  An unusual occurrence of Kleine-Levin syndrome in a man with refractory immune thrombocytopenic purpura: a case report.

Authors:  Hamed Amirifard; Farzaneh Barzkar; Seyed Amirhossein Fazeli; Seyed Mehdi Hashemi
Journal:  J Med Case Rep       Date:  2015-04-01

6.  Expression, purification and biological activity assessment of romiplostim biosimilar peptibody.

Authors:  Shima Fayaz; Pezhman Fard-Esfahani; Majid Golkar; Mojgan Allahyari; Sedigheh Sadeghi
Journal:  Daru       Date:  2016-07-11       Impact factor: 3.117

7.  Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist.

Authors:  Chengying Xie; Huajun Zhao; Xubin Bao; Haoyu Fu; Liguang Lou
Journal:  J Cell Mol Med       Date:  2018-08-29       Impact factor: 5.310

8.  Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.

Authors:  Connie L Erickson-Miller; Evelyne Delorme; Shin-Shay Tian; Christopher B Hopson; Amy J Landis; Elizabeth I Valoret; Teresa S Sellers; Jon Rosen; Stephen G Miller; Juan I Luengo; Kevin J Duffy; Julian M Jenkins
Journal:  Stem Cells       Date:  2009-02       Impact factor: 6.277

9.  Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura.

Authors:  Shoko Goto; Hiroaki Goto; Reo Tanoshima; Hiromi Kato; Hiroyuki Takahashi; Osamu Sekiguchi; Sumio Kai
Journal:  Int J Hematol       Date:  2009-03-24       Impact factor: 2.319

10.  The effect of single course high dose dexamethasone on CD28/CTLA-4 balance in the treatment of patients with newly diagnosed primary immune thrombocytopenia.

Authors:  Xinhong Guo; Halida Yasen; Fang Zhao; Lei Wang; Mingling Sun; Nannan Pang; Xiujuan Wang; Ying Zhang; Jianbing Ding; Xiumin Ma
Journal:  Hum Vaccin Immunother       Date:  2015-07-25       Impact factor: 3.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.